Therefore, further research should focus on the cost-effectiveness of cystatin C-based measurements of CKD, especially in low-risk settings and older populations with the aim of finding ways to reduce the costs of measurement within routine medical care. This evidence concerns the gene CST3 and chronic kidney disease.